Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

71 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

On-Study Form NSCLC Stage I-III

- 20-09-21 - 1 Formulier, 8 Itemgroepen, 65 Data-elementen, 1 Taal
Itemgroepen: CRF Header, Pre-Treatment Characteristics , Disease Description - Stage I-III, Prior Treatment NSCLC Stage I-III, Prior Systemic Therapy NSCLC Advanced, Surgical Procedure Description , Prior Radiation Therapy NSCLC Advanced, Comments
Phase II Consortium - Phase II Lung Cancer - NSCLC Stage I-III On-Study Form (for Adjuvant Studies and Inoperable Stage III) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF3F2FE3-D320-46AD-E034-0003BA3F9857

Lung Cancer NCT00946712 Pre-Study - Southwest Oncology Group S0819 Prestudy Form - 2863901v1.0 - Southwest Oncology Group S0819 Prestudy Form

- 20-09-21 - 1 Formulier, 8 Itemgroepen, 72 Data-elementen, 1 Taal
Itemgroepen: Header Module, PATIENT AND DISEASE DESCRIPTION, PATIENT AND DISEASE DESCRIPTION1, LABORATORY VALUES, LABORATORY VALUES1, ADDITIONAL PRESTUDY DATA, PRIOR TREATMENT RELATED TO THIS CANCER, Comments
Southwest Oncology Group S0819 Prestudy Form Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=684FE956-5AAF-A7DA-E040-BB89AD432A2B

On-Study - Phase II Lung Cancer - NSCLC Advanced On-Study Form - 2398811v1.0 - Phase II Lung Cancer - NSCLC Advanced On-Study Form

- 20-09-21 - 1 Formulier, 8 Itemgroepen, 55 Data-elementen, 1 Taal
Itemgroepen: CRF Header, Pre-Treatment Characteristics , Disease Description NSCLC ADVANCED, Prior Treatment - NSCLC Advanced, Prior Systemic Therapy NSCLC Advanced, Surgical Procedure Description , Prior Radiation Therapy - NSCLC Advanced, Comments
Phase II Consortium - Phase II Lung Cancer - NSCLC Advanced On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF7A9F25-B26C-5224-E034-0003BA3F9857

Lung Cancer NCT01107626 Eligibility - E5508 Registration Worksheet (step 2) - 3078042v1.0 - E5508 Registration Worksheet (step 2)

- 17-09-21 - 1 Formulier, 3 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Eligibility, Demographic Data Required For Patient Registration, I have reviewed the above data and agree the date are accurate and correct
E5508 Registration Worksheet (step 2) Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8528E45F-A327-F490-E040-BB89AD4356FC

Eligibility NCT00981058 Non Small Cell Lung Cancer - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 30 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00981058

Eligibility NCT00982111 Non Small Cell Lung Cancer - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 29 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00982111

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Module 2 - Laboratory Tests - Haematology; Blood Chemistry; Urinalysis

- 28-04-21 - 1 Formulier, 4 Itemgroepen, 21 Data-elementen, 1 Taal
Itemgroepen: Administrative, Laboratory Tests - Haematology, Laboratory Tests - Blood Chemistry, Laboratory Tests - Urinalysis
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Laboratory Tests - Haematology; Blood Chemistry; Urinalysis

- 21-04-21 - 1 Formulier, 4 Itemgroepen, 28 Data-elementen, 1 Taal
Itemgroepen: Administrative, Laboratory Tests - Haematology, Laboratory Tests - Blood Chemistry, Laboratory Tests - Urinalysis
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Eligibility Criteria

- 20-04-21 - 1 Formulier, 5 Itemgroepen, 27 Data-elementen, 1 Taal
Itemgroepen: Administrative, Inclusion Criteria, Exclusion Criteria, Inclusion/ Exclusion, Investigator's Signature
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Screening - Toxicities Related to Previous Radiotherapy for SCLC; 12-Lead Electrocardiogram; Diagnostic Studies for Tumor Assessment; Ongoing Medical Conditions Associated with SCLC; Significant Medical/Surgical History and Physical Examination

- 17-04-21 - 1 Formulier, 9 Itemgroepen, 20 Data-elementen, 1 Taal
Itemgroepen: Administrative, Toxicities related to previous Radiotherapy for SCLC, Toxicities related to previous Radiotherapy for SCLC, 12-Lead Electrocardiogram, Diagnostic Studies for Tumor Assessment, Ongoing Medical Conditions Associated with SCLC, Ongoing Medical Conditions Associated with SCLC, Significant Medical/ Surgical History and Physical Examination, Significant Medical/ Surgical History and Physical Examination
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Day 1 Pre-Dose -Vital Signs; Pharmacogenetic Research Consent/ Blood Sample Collection; Investigational Product Compliance (Pazopanib); Investigational Product (First Dose); Biomarker Samples

- 16-05-19 - 1 Formulier, 6 Itemgroepen, 30 Data-elementen, 1 Taal
Itemgroepen: Date of visit/ assessment, Vital Signs, Pharmacogenetic Research Consent/ Blood Sample Collection, Investigational Product Compliance - Pazopanib, Investigational Product - First Dose, Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Vargatef 2nd line therapy in NSCLC NCT02392455 - Eligibility Criteria

- 14-05-19 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT02392455 Brief Summary: This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial